Statistics
Total Visits
Views | |
---|---|
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study(legacy) | 114 |
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study(legacy) | 85 |
Total Visits per Month
November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | May 2024 | |
---|---|---|---|---|---|---|---|
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study | 6 | 3 | 1 | 3 | 2 | 0 | 1 |
File Downloads
Views |
---|
Top Country Views
Views | |
---|---|
United States | 53 |
China | 21 |
Australia | 15 |
France | 12 |
Germany | 9 |
Netherlands | 8 |
Vietnam | 8 |
Spain | 2 |
Bangladesh | 1 |
Brazil | 1 |
Top City Views
Views | |
---|---|
Ashburn | 19 |
Kaleen | 12 |
Hanoi | 8 |
Rotterdam | 8 |
Fairfield | 7 |
Beijing | 6 |
Zhengzhou | 5 |
Changchun | 3 |
Des Moines | 3 |
Madrid | 2 |